美罗培南-巴坦治疗严重革兰氏阴性菌感染患者临床结局与安全性的真实世界多中心分析
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.
作者信息
Alosaimy Sara, Jorgensen Sarah C J, Lagnf Abdalhamid M, Melvin Sarah, Mynatt Ryan P, Carlson Travis J, Garey Kevin W, Allen David, Venugopalan Veena, Veve Michael, Athans Vasilios, Saw Stephen, Yost Christine N, Davis Susan L, Rybak Michael J
机构信息
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA.
出版信息
Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar.
Abstract
Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.
摘要
40例患者接受美罗培南-巴坦（MEV）治疗严重革兰氏阴性菌（GNB）感染。耐碳青霉烯类（CRE）占所有GNB感染的80.0%。70.0%的患者临床治疗成功。30天的死亡率和复发率分别为7.5%和12.5%。1例患者可能因MEV出现皮疹皮疹皮疹。
相似文献
1
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.
Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar.
2
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00567-17. Print 2017 Sep.
3
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and .
Open Forum Infect Dis. 2021 Jul 14;8(8):ofab371. doi: 10.1093/ofid/ofab371. eCollection 2021 Aug.
4
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
5
Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5.
6
Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. Epub 2018 Apr 19.
7
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.
8
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.
9
Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01446-17. Print 2018 Jan.
10
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Future Microbiol. 2018 Jul;13(9):971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.
引用本文的文献
1
Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.
JAC Antimicrob Resist. 2025 Jun 19;7(3):dlaf096. doi: 10.1093/jacamr/dlaf096. eCollection 2025 Jun.
2
Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence.
Infect Dis Ther. 2025 May;14(5):973-989. doi: 10.1007/s40121-025-01146-x. Epub 2025 Apr 12.
3
Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.
Pathogens. 2025 Feb 1;14(2):130. doi: 10.3390/pathogens14020130.
4
Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0173624. doi: 10.1128/aac.01736-24. Epub 2025 Feb 7.
5
National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for .
Antibiotics (Basel). 2024 Dec 1;13(12):1152. doi: 10.3390/antibiotics13121152.
6
Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Int J Mol Sci. 2024 Sep 4;25(17):9574. doi: 10.3390/ijms25179574.
7
Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.
Antibiotics (Basel). 2024 Jul 5;13(7):629. doi: 10.3390/antibiotics13070629.
8
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.
Open Forum Infect Dis. 2024 May 8;11(6):ofae273. doi: 10.1093/ofid/ofae273. eCollection 2024 Jun.
9
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.
World J Emerg Surg. 2024 Jun 8;19(1):23. doi: 10.1186/s13017-024-00551-w.
10
Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance.
Antibiotics (Basel). 2023 Nov 10;12(11):1612. doi: 10.3390/antibiotics12111612.
本文引用的文献
1
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
Clin Infect Dis. 2020 Jul 27;71(3):667-671. doi: 10.1093/cid/ciz1131.
2
A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?
BMC Infect Dis. 2018 Dec 5;18(1):625. doi: 10.1186/s12879-018-3524-8.
3
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.
4
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.
5
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28.
6
Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in the Emergency Department.
Clin Infect Dis. 2017 Oct 15;65(8):1253-1259. doi: 10.1093/cid/cix548.
7
Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S30-S35. doi: 10.1093/cid/ciw829.
8
A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.
Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024.
9
Impact of Source Control in Patients With Severe Sepsis and Septic Shock.
Crit Care Med. 2017 Jan;45(1):11-19. doi: 10.1097/CCM.0000000000002011.
10
Treating infections caused by carbapenemase-producing Enterobacteriaceae.
Clin Microbiol Infect. 2014 Sep;20(9):862-72. doi: 10.1111/1469-0691.12697. Epub 2014 Jul 12.
Zotero 插件